For the most part, ZS’ Brian Chapman sounds positive about medtech 2019. He expects progress made in 2018 to continue into this year, including ongoing collaboration with regulatory bodies, use of real-world evidence to drive reimbursement discussions and advances in digital health. Nevertheless, he warns that storms are brewing, especially geopolitically. Find out how the potential impact of the U.S./China trade war and uncertainty in Brazil and Brexit could affect the industry–and why it has an influence on M&A activity. Learn why he expects to see more new entrants in the healthcare space–and why that’s both a risk and an opportunity for medtech incumbents.